Second-Line Agents Delay Insulin Versus Secretagogues in Type 2 Diabetes
This large UK target-trial emulation gives pharmacists real-world comparative data on which post-metformin agents prolong time to insulin, directly informing second-line selection conversations.
📅 Journal publication: Oct 2026(online Aug 6, 2026)·Last updated: Oct 7, 2026
Second-line antidiabetic drugs play a key role in delaying insulin therapy.
Understanding how second-line antidiabetic drugs affect the progression to insulin can help optimize treatment plans for type 2 diabetes. Thiazolidinediones (TZDs), dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-glucose co-transporter 2 (SGLT-2) inhibitors were associated with a lower risk of insulin initiation compared to insulin secretagogues, with hazard ratios of 0.59, 0.75, and 0.62 respectively. These findings suggest that TZDs, DPP-4 inhibitors, and SGLT-2 inhibitors may be preferable for extending the duration before insulin is needed, although risks of treatment modification vary. Select TZDs, DPP-4 inhibitors, or SGLT-2 inhibitors to potentially delay insulin initiation after metformin in type 2 diabetes.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Authors:Yu YH, Zhang Q, Zapata-Bravo E, Platt RW, Reynier P, Yu OHY, Filion KB
Citation:Yu YH, Zhang Q, Zapata-Bravo E, et al. Time to Insulin Initiation Among Patients With Type 2 Diabetes Treated With Second-Line Antidiabetic Drugs. Diabetes, obesity & metabolism. 2026;28(10):9655-9667. doi:10.1111/dom.71182
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.